Premium Tesamorelin Peptide for Sale | 5mg Lyophilized Powder | ≥99% Purity | 48-Hour Delivery Across EU & UK

Tesamorelin: The Synthetic GHRH Analog at the Forefront of Metabolic Research

Buy Tesamorelin 5mg Online EU & UK, eupeptidelap.co.uk is proud to present Tesamorelin 5mg, a premium research-grade growth hormone-releasing hormone (GHRH) analog manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Tesamorelin for sale that delivers exceptional purity, consistency, and documented quality for advanced studies in endocrinology, metabolic regulation, and adipose tissue biology .

Tesamorelin is a synthetic 44-amino acid polypeptide analogue of growth hormone-releasing hormone (GHRH), engineered with a specific modification (a trans-3-hexenoyl group) that enhances its stability and resistance to enzymatic degradation in the bloodstream, resulting in a longer half-life and more sustained effect compared to its natural counterpart . With a molecular formula of C₂₂₁H₃₆₆N₇₂O₆₇S and a molecular weight of approximately 5135.9 g/mol, this sophisticated peptide is identical in sequence to human GHRH but with improved pharmacokinetic properties .

Tesamorelin works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH) . This pulsatile release mimics the body’s natural pattern of GH secretion, which is critical for its beneficial metabolic effects and helps avoid the continuous supraphysiological levels associated with direct growth hormone administration . The released GH subsequently stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which mediates many of the peptide’s anabolic and metabolic actions on target cells including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes .

For researchers seeking to buy peptide online EU for investigations into visceral adipose tissue reduction, metabolic disorders, or age-related endocrine changes, eupeptidelap.co.uk offers this premium research compound with comprehensive documentation, including Certificates of Analysis and batch-specific purity data. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our guaranteed 48 hour delivery peptide service ensures your research continues without interruption.

The Scientific Foundation of Tesamorelin Research

Development and Clinical Background

Tesamorelin was developed as a targeted therapy for HIV-associated lipodystrophy, a condition characterized by abnormal fat redistribution including visceral fat accumulation, and received US Food and Drug Administration approval in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy . Its unique mechanism of restoring pulsatile GH secretion offers a more physiological approach to addressing GH deficiency compared to direct GH administration. Buy Tesamorelin 5mg Online EU & UK

Mechanism of Action: GHRH Receptor Activation

Tesamorelin exerts its effects through selective activation of GHRH receptors on pituitary somatotroph cells . This activation initiates a cascade of endocrine events:

Pituitary Stimulation: After subcutaneous administration, tesamorelin binds to specific GHRH receptors on the surface of pituitary cells called somatotrophs, triggering the synthesis and release of growth hormone .

Pulsatile GH Release: The stimulation results in a significant yet pulsatile increase in circulating GH levels, preserving the body’s natural secretion pattern characterized by periodic bursts, primarily during sleep . This physiological pattern is critical for optimizing metabolic benefits while potentially mitigating side effects associated with continuous high-level GH exposure .

IGF-1 Production: The released GH travels to the liver, its primary target organ, where it stimulates production and secretion of insulin-like growth factor-1 (IGF-1), a primary mediator of GH’s anabolic and metabolic effects throughout the body .

Selective Receptor Binding: In vitro studies demonstrate that tesamorelin binds and stimulates human GRF receptors with similar potency as endogenous GHRH .

Pharmacokinetic Profile

Tesamorelin exhibits unique pharmacokinetic properties that distinguish it from other GHRH analogs:

Parameter	Value
Absolute Bioavailability	<4% after subcutaneous administration
Peak Concentration (Tmax)	Median 0.15 hours (approximately 9 minutes)
Half-Life (t½)	Approximately 11 minutes in healthy subjects
Volume of Distribution	4.8 ± 1.9 L/kg
Metabolism	No formal metabolism studies performed in humans; metabolized locally by receptor-bearing cells
Elimination	Rapid clearance from circulation

Notably, tesamorelin exposure (AUC) is approximately 34% higher in HIV-infected patients than healthy subjects, while peak plasma concentrations remain similar between populations .

Selectivity Profile

Tesamorelin demonstrates remarkable selectivity for the GH axis. Clinical trials have shown no clinically significant changes in levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), and prolactin . This selectivity minimizes confounding variables in endocrine research applications.

Key Research Applications

Visceral Adipose Tissue (VAT) Research

Tesamorelin’s most extensively documented effect is its ability to selectively reduce visceral adipose tissue, the metabolically active deep abdominal fat surrounding vital organs that contributes significantly to metabolic disease, inflammation, and cardiovascular risk . A comprehensive meta-analysis of randomized controlled trials published in 2026 demonstrated:

Significant VAT Reduction: Tesamorelin treatment was associated with significant reduction in visceral adipose tissue (mean difference = -27.71 cm², 95% CI [-38.37, -17.06]; P < 0.001)
Trunk Fat Decrease: Mean reduction of -1.18 kg (95% CI [-1.40, -0.96]; P < 0.001)
Waist Circumference Reduction: Mean decrease of -1.61 cm (95% CI [-2.28, -0.95]; P < 0.001)
Selective Targeting: Tesamorelin selectively targets visceral fat with minimal to no effect on beneficial subcutaneous adipose tissue

In landmark Phase 3 trials, patients receiving daily 2 mg injections of tesamorelin for 26 weeks experienced statistically significant reductions in VAT averaging approximately 15-18% . Extension studies demonstrated that continued treatment for up to 52 weeks led to sustained reductions, though VAT levels began to return toward baseline upon cessation, indicating that ongoing therapy is necessary to maintain benefits. Buy Tesamorelin 5mg Online EU & UK

Hepatic Fat Research

Emerging evidence supports tesamorelin’s efficacy in reducing hepatic fat accumulation, making it valuable for research into metabolic dysfunction-associated steatotic liver disease (MASLD):

Hepatic Fat Reduction: The 2026 meta-analysis demonstrated significant reduction in hepatic fat percentage (mean difference = -4.28%, 95% CI [-6.31, -2.24]; P < 0.001)
Mechanism: GH directly stimulates lipolysis in hepatocytes and reduces de novo lipogenesis
Clinical Relevance: Hepatic lipid accumulation is a critical health concern associated with increased cardiovascular risk

Body Composition and Lean Mass Research

Beyond fat reduction, tesamorelin has demonstrated significant anabolic effects on lean body mass:

Lean Body Mass Increase: Meta-analysis revealed significant increase in lean body mass (mean difference = 1.42 kg, 95% CI [1.13, 1.71]; P < 0.001)
Muscle Quality: Research indicates tesamorelin decreases intramyocellular lipid content (myosteatosis) and increases muscle density, improving muscle quality
Sarcopenia Research: These findings suggest potential applications for investigating age-related muscle loss and conditions characterized by muscle mass decline

Metabolic and Lipid Profile Research

Tesamorelin’s effects extend to multiple metabolic parameters:

Lipid Improvements: Studies have demonstrated reductions in triglycerides and improvements in lipid profiles
Glucose Homeostasis: Importantly, tesamorelin maintains a neutral glycemic profile without worsening insulin resistance
Non-HIV Populations: Research in non-HIV individuals with abdominal obesity showed significant VAT reduction and improved lipid profiles, suggesting benefits are not limited to specific disease states

HIV-Associated Lipodystrophy Research

As the condition for which tesamorelin received FDA approval, HIV-associated lipodystrophy remains a primary research application. This syndrome affects 8-84% of patients on antiretroviral therapy and is characterized by abnormal fat redistribution, metabolic complications, body image concerns, and increased cardiovascular risks . Tesamorelin’s ability to restore GH pulsatility—which is frequently reduced in this population—makes it particularly relevant for studying this condition .

Aging and Neuroendocrine Research

Age-related decline in GH secretion (somatopause) is associated with reduced cellular repair, bone density loss, and decreased cognitive vitality. Tesamorelin’s ability to restore GH pulsatility makes it valuable for investigating strategies to mitigate age-related decline and for studying growth hormone dynamics, muscle preservation, and metabolic balance in aging models .

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Tesamorelin 5mg from certified GMP facilities with rigorous quality control protocols:

HPLC Purity Analysis: ≥99% purity verified by high-performance liquid chromatography, with some suppliers reporting >99.1% purity
Mass Spectrometry Verification: Molecular weight confirmation (5135.9 g/mol) via LC-HRMS
Batch-Specific Certificates of Analysis: Complete documentation for each production run
Third-Party Testing: Independent verification including endotoxin and elemental impurity screening
Research-Use Only (RUO) Labeling: Full compliance with research compound regulations

Chemical and Product Specifications

Specification	Detail
Product Name	Tesamorelin (TH9507, GHRH Analog)
CAS Number	218949-48-5
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	5135.9 g/mol
Amino Acid Length	44 amino acids
Purity	≥99% (HPLC verified)
Appearance	White to off-white lyophilized powder
Form	Lyophilized powder in sterile vials
Solubility	Soluble in sterile water or aqueous buffers
Storage (Lyophilized)	≤6°C to -20°C; protect from light, heat, and moisture
Half-Life	Approximately 11 minutes
Bioavailability	<4% after subcutaneous administration
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Stability and Handling Guidelines

Lyophilized Powder Storage: Store lyophilized tesamorelin powder at -20°C or at ≤6°C in a dry, dark environment, protected from light, heat, and moisture . Under proper storage conditions, the powder maintains stability for up to 24 months from the date of manufacture. Buy Tesamorelin 5mg Online EU & UK

Reconstitution Protocol:

Allow vial and solvent to reach ambient temperature before opening to prevent condensation
Reconstitute using sterile 18MΩ-cm H₂O or bacteriostatic water according to research protocol
Inject solvent slowly down the inside wall of the vial to minimize foaming
Gently swirl or roll the vial until fully dissolved—do not shake vigorously
Label the vial with the date of reconstitution
Refrigerate immediately at 2-8°C

Reconstituted Solution Storage: Store reconstituted tesamorelin at 2-8°C for short-term use (typically 2-7 days). For longer-term storage, aliquot into single-use portions and store at -80°C. Avoid repeated freeze-thaw cycles as this can degrade the peptide. Buy Tesamorelin 5mg Online EU & UK

Protection from Light and Moisture:

Store in original packaging protected from light
Keep vials tightly sealed when not in use
Allow refrigerated vials to reach room temperature before opening to prevent condensation

Key Benefits

Premium Quality Manufacturing: GMP-certified production, ≥99% HPLC-verified purity with lot-specific COAs
Clinically Validated Peptide: FDA-approved for HIV-associated lipodystrophy; extensively studied in over 800 patients in Phase 3 trials
Selective VAT Reduction: Reduces visceral adipose tissue by -27.71 cm² in meta-analysis (P < 0.001)
Hepatic Fat Reduction: Decreases hepatic fat percentage by -4.28% (P < 0.001)
Lean Mass Preservation: Increases lean body mass by 1.42 kg (P < 0.001)
Pulsatile GH Secretion: Restores physiological GH pulsatility rather than continuous elevation
Pituitary Selectivity: No significant effects on TSH, LH, ACTH, or prolactin
Metabolic Research: Ideal for studying visceral adiposity, lipodystrophy, and body composition
MASLD/NAFLD Research: Significant hepatic fat reduction for liver disease studies
Aging Research: Potential applications in somatopause and age-related endocrine decline
Muscle Quality Research: Decreases myosteatosis and improves muscle density
Well-Characterized Safety Profile: Favorable safety profile in clinical trials with mild to moderate, manageable adverse events
Lipid Profile Improvement: Reduces triglycerides and improves lipid parameters
Neutral Glycemic Effects: No significant perturbation of glucose homeostasis
Growth Hormone Research: Valuable tool for investigating GH-IGF-1 axis dynamics
Comprehensive Documentation: Certificates of Analysis with batch-specific purity data
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
EU Sourced: Available from within the European Union

Frequently Asked Questions

Q: What is Tesamorelin and how does it work?

A: Tesamorelin is a synthetic 44-amino acid analogue of growth hormone-releasing hormone (GHRH) engineered with a stabilizing modification that enhances its resistance to enzymatic degradation . It works by binding to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone . This pulsatile pattern mimics natural GH secretion, leading to increased IGF-1 production and subsequent effects on adipose tissue, muscle, and metabolism .

Q: What is the difference between Tesamorelin and Sermorelin?

A: Sermorelin represents only the first 29 amino acids of the GHRH sequence, while Tesamorelin contains the full 44-amino acid sequence plus a stabilizing modification. This structural difference makes Tesamorelin significantly more potent and stable, with a longer half-life and more sustained effect compared to Sermorelin .

Q: What purity level can I expect when I buy Tesamorelin from eupeptidelap.co.uk?

A: All Tesamorelin 5mg from eupeptidelap.co.uk is tested to ≥99% purity by HPLC, with some batches achieving >99.1% purity . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: What is the molecular weight and CAS number of Tesamorelin?

A: Tesamorelin has a molecular weight of approximately 5135.9 g/mol and CAS number 218949-48-5 . Its molecular formula is C₂₂₁H₃₆₆N₇₂O₆₇S .

Q: What research areas commonly use Tesamorelin?

A: Tesamorelin is widely used in visceral adipose tissue (VAT) research, hepatic fat and MASLD/NAFLD studies, body composition research, HIV-associated lipodystrophy research, metabolic and lipid profile studies, aging and somatopause research, and growth hormone dynamics investigations .

Q: How should I store Tesamorelin for long-term stability?

A: Store lyophilized tesamorelin powder at -20°C or ≤6°C in a dry, dark environment, protected from light, heat, and moisture . Under proper storage conditions, the powder maintains stability for up to 24 months from the date of manufacture. After reconstitution, store at 2-8°C for short-term use (2-7 days) and aliquot into single-use portions for longer-term storage at -80°C.

Q: What is the half-life of Tesamorelin?

A: The mean elimination half-life of tesamorelin is approximately 11 minutes in healthy subjects after subcutaneous administration . Despite this short plasma half-life, its effects on GH pulsatility and downstream metabolic processes persist much longer due to the biological cascade it initiates.

Q: Does Tesamorelin affect other pituitary hormones?

A: No. Clinical trials have demonstrated no clinically significant changes in levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), and prolactin, making it highly selective for the GH axis .

Q: What is the evidence for Tesamorelin’s effects on visceral fat?

A: A comprehensive 2026 meta-analysis of randomized controlled trials demonstrated that tesamorelin significantly reduces visceral adipose tissue (mean difference = -27.71 cm², 95% CI [-38.37, -17.06]; P < 0.001), trunk fat (-1.18 kg), waist circumference (-1.61 cm), and hepatic fat percentage (-4.28%) . Phase 3 trials showed average VAT reductions of 15-18% over 26 weeks .

Q: Do you ship Tesamorelin to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Tesamorelin 5mg to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use protective packaging to maintain compound integrity during transit.

Q: What documentation do you provide with Tesamorelin orders?

A: Every order includes a Certificate of Analysis (COA) with batch-specific purity data . Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification.

Q: Does Tesamorelin have applications in non-HIV research?

A: Yes. Research in non-HIV individuals with abdominal obesity has shown similar benefits, including significant VAT reduction and improved lipid profiles, suggesting tesamorelin’s effects are not limited to specific disease states but are a direct result of its mechanism of action on the GH axis .

Q: What are the common adverse effects observed in Tesamorelin clinical trials?

A: Common adverse events include injection site reactions (redness, pain, itching), arthralgia (joint pain), myalgia (muscle pain), peripheral edema, and paresthesia . These effects are generally mild to moderate and manageable. Anti-tesamorelin antibodies developed in approximately 50% of patients, but antibody status did not affect treatment efficacy .

Q: Do you offer bulk quantities of Tesamorelin for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs. ...........................................

Advance Your Research with Tesamorelin 5mg

eupeptidelap.co.uk is your trusted source for Tesamorelin 5mg, the premium choice for researchers investigating visceral adiposity, metabolic disorders, hepatic fat accumulation, and growth hormone dynamics. With over a decade of clinical research, FDA approval for HIV-associated lipodystrophy, and extensive peer-reviewed literature supporting its metabolic effects, tesamorelin represents one of the most clinically validated GHRH analogs in the research community .

Whether you are exploring visceral fat reduction mechanisms, designing MASLD/NAFLD studies, investigating body composition changes, or researching age-related endocrine decline, our rigorously tested compound provides the quality and consistency your work demands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.

primary hyperparathyroidism

Tesamorelin 5mg